Edgestream Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Edgestream Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.1M	Buy	+66,573	New	+$3.2M	0.09%	398
2026 Q1	–	Sell	-100,018	Closed	-$4.97M	–	1100
2025 Q4	$4.97M	Buy	+100,018	New	+$4.86M	0.14%	245
2024 Q3	–	Sell	-75,843	Closed	-$2.03M	–	1071
2024 Q2	$2.03M	Buy	+75,843	New	+$2.2M	0.1%	328
2023 Q4	–	Sell	-9,061	Closed	-$250K	–	1056
2023 Q3	$250K	Buy	9,061 +1,775	+24%	+$54K	0.02%	758
2023 Q2	$219K	Buy	+7,286	New	+$255K	0.02%	678

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Edgestream Partners's SUPN Position: Q2 2026 in Review

Edgestream Partners opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 66,573 shares worth $3.1M. The stake represents 0.09% of the portfolio and ranks #398 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in SUPN as recently as Q4 2025.

Edgestream Partners first reported a position in SUPN in Q2 2023 and has held it in 5 quarters since. The position peaked at $4.97M in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Edgestream Partners held 66,573 shares of Supernus Pharmaceuticals worth $3.1M as of Q2 2026.
Supernus Pharmaceuticals was a new Edgestream Partners position in Q2 2026.
Supernus Pharmaceuticals made up 0.09% of Edgestream Partners's portfolio in Q2 2026, its #398 holding.
Edgestream Partners first reported a position in Supernus Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
Edgestream Partners's Supernus Pharmaceuticals position peaked at $4.97M in Q4 2025.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.